tiprankstipranks
Bayer AG (BAYRY)
OTHER OTC:BAYRY
Want to see BAYRY full AI Analyst Report?

Bayer (BAYRY) Price & Analysis

2,108 Followers

BAYRY Stock Chart & Stats

$11.02
-$0.08(-1.46%)
At close: 4:00 PM EST
$11.02
-$0.08(-1.46%)

Bulls Say, Bears Say

Bulls Say
Strategic Crop-business ConsolidationBayer’s move to fold U.S. glyphosate operations into Ruveon is a structural repositioning that creates a dedicated, more nimble unit focused on commodity market dynamics. Over the medium term this can sharpen go-to-market execution, reduce complexity in Crop Science and improve margins and competitiveness in the U.S. glyphosate market.
Positive Operating And Free Cash FlowBayer continues to generate positive operating and free cash flow even while net income is negative. Persistent cash generation provides a durable buffer to fund R&D, service debt, and support strategic initiatives without immediate reliance on equity issuance, enhancing resilience during a multi-year turnaround.
Strong Gross Margins Across SegmentsSustained ~59% gross margins indicate healthy underlying product economics and pricing power across businesses. This structural margin strength supports operating leverage as sales recover, helps absorb fixed costs, and underpins longer-term profitability potential once top-line declines are arrested.
Bears Say
Multi-year Revenue DeclineA persistent top-line contraction (TTM ~-25% YoY) erodes scale benefits, weakens pricing power, and strains R&D payback. Without durable new product growth or market share gains, revenue decline undermines the business’s ability to restore sustainable operating margins and long-term EPS recovery.
Ongoing Net LossesSustained net losses reduce retained earnings and constrain returns to shareholders, while limiting reinvestment capacity. Persistent negative profitability increases reliance on cash reserves or external financing and raises execution risk for turnaround plans, especially if top-line recovery stalls.
Elevated Leverage Reduces FlexibilityLeverage near 1.35x equity constrains financial flexibility for acquisitions, R&D scaling, or prolonged investment in turnaround initiatives. Higher debt increases interest and refinancing risk, leaving less room to absorb cyclical swings in Crop Science and pressuring capital allocation choices over the medium term.

Bayer News

BAYRY FAQ

What was Bayer AG’s price range in the past 12 months?
Bayer AG lowest stock price was $7.26 and its highest was $14.56 in the past 12 months.
    What is Bayer AG’s market cap?
    Bayer AG’s market cap is $54.80B.
      When is Bayer AG’s upcoming earnings report date?
      Bayer AG’s upcoming earnings report date is Aug 04, 2026 which is in 33 days.
        How were Bayer AG’s earnings last quarter?
        Bayer AG released its earnings results on May 12, 2026. The company reported $0.795 earnings per share for the quarter, beating the consensus estimate of $0.676 by $0.119.
          Is Bayer AG overvalued?
          According to Wall Street analysts Bayer AG’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Bayer AG pay dividends?
            Bayer AG pays a Annually dividend of $0.032 which represents an annual dividend yield of 0.29%. See more information on Bayer AG dividends here
              What is Bayer AG’s EPS estimate?
              Bayer AG’s EPS estimate is 0.23.
                How many shares outstanding does Bayer AG have?
                Bayer AG has 3,929,696,000 shares outstanding.
                  What happened to Bayer AG’s price movement after its last earnings report?
                  Bayer AG reported an EPS of $0.795 in its last earnings report, beating expectations of $0.676. Following the earnings report the stock price went up 3.278%.
                    Which hedge fund is a major shareholder of Bayer AG?
                    Currently, no hedge funds are holding shares in BAYRY
                    What is the TipRanks Smart Score and how is it calculated?
                    Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                      Company Description

                      Bayer AG

                      Bayer Aktiengesellschaft, commonly known as Bayer AG, functions as a prominent global life sciences company through its various subsidiaries. Its extensive operations are strategically segmented into Pharmaceuticals, Consumer Health, and Crop Science. The Pharmaceuticals division concentrates on developing and marketing prescription medications, with key areas including cardiology and women's healthcare. It also offers specialized therapeutic solutions for oncology, hematology, and ophthalmology, alongside diagnostic imaging equipment, contrast agents, and advanced cell and gene therapies. Bayer's Consumer Health segment provides a wide array of non-prescription (over-the-counter) medicines, medical devices, medicated skincare items, and nutritional supplements. These self-care products address diverse health needs such as dermatology, dietary support, pain relief, cardiovascular risk prevention, digestive issues, allergy management, and cold and cough symptoms. The Crop Science division supports the agricultural sector with chemical and biological crop protection products, genetically enhanced plant traits, seeds, digital farming tools, and solutions for pest and weed control. This segment also manages the breeding, propagation, production, and specialized treatment of seeds, complemented by dedicated customer service for farmers. Bayer is actively involved in numerous strategic collaborations to bolster its research and development pipeline. These partnerships include an agreement with MD Anderson Cancer Center for oncology drug development, a research and licensing deal with Dewpoint Therapeutics, Inc. focused on novel treatments for cardiovascular and gynecological diseases, and collaborations with Exscientia Ltd, Foundation Medicine Inc., Evotec AG, and Arvinas Inc. Additionally, the company maintains strategic research alliances with the University of Oxford for gynecological therapies and with Kyoto University to discover potential new drugs for pulmonary conditions. The company’s products reach a broad market through various distribution channels, including wholesale partners, independent and chain pharmacies, supermarkets, online and other retail outlets, hospitals, and direct sales to agricultural producers. Bayer Aktiengesellschaft was established in 1863 and is headquartered in Leverkusen, Germany.

                      Bayer (BAYRY) Earnings & Revenues

                      BAYRY Earnings Call

                      Q1 2026
                      0:00 / 0:00
                      Earnings Call Sentiment|Neutral
                      The call balanced clear operational progress—delivery of raised guidance, improved launch momentum in Pharma, meaningful DSO-driven cost savings, and a reduced net financial debt position in 2025—against substantial legal and cashflow headwinds. Management articulated tangible growth drivers across Crop Science, Pharma and Consumer Health and concrete cost-savings milestones, but also disclosed large litigation provisions (EUR 11.8 billion liabilities), expected negative free cash flow in 2026 due to ~EUR 5 billion litigation-related payouts, projected net debt increase and significant product declines (notably Xarelto and Eylea). Given the mix of strong operational execution and material financial/legal risks that will weigh on near-term cash flow and balance-sheet metrics, the tone of the call is cautiously constructive but realistic about the challenges ahead.View all BAYRY earnings summaries
                      Similar Stocks
                      Company
                      Price & Change
                      Follow
                      Bristol-Myers Squibb
                      Gilead Sciences
                      GlaxoSmithKline
                      Pfizer
                      Sanofi

                      Ownership Overview

                      0.17%0.17%99.66%
                      Insiders
                      0.17% Other Institutional Investors
                      99.66% Public Companies and
                      Individual Investors

                      Options Prices

                      Currently, No data available
                      ---
                      Popular Stocks